Why Cytokinetics Stock Was a Nearly 5% Winner Today

Published on 20 Dec 2024 on Motley Fool · via Yahoo Finance

Why Cytokinetics Stock Was a Nearly 5% Winner Today

This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics originally sold those rights to...

Read the rest of the article

NASDAQ.SNY price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Is Moderna a Bad-News Buy for 2025?

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a cor...

Motley Fool · via Yahoo Finance 16 Jan 2025

FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition

Merck is developing tulisokibart, a novel TL1A inhibitor, for the treatment of UC, CD and other...

Zacks · via Yahoo Finance 16 Jan 2025

Kymera Provides Pipeline Objectives for 2025, Stock Gains

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 mill...

Zacks · via Yahoo Finance 15 Jan 2025

France stocks higher at close of trade; CAC 40 up 0.20% By Investing.com

France stocks higher at close of trade; CAC 40 up 0.20%

Investing.com 14 Jan 2025

IGM Biosciences downgraded to Hold from Buy at Jefferies

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from...

TipRanks · via Yahoo Finance 11 Jan 2025

IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce

IGMS stock fell 68% during Friday's trading session on the news. The business is stopping further...

GuruFocus.com · via Yahoo Finance 10 Jan 2025

SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stag...

Zacks · via Yahoo Finance 10 Jan 2025

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In...

On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating th...

Benzinga · via Yahoo Finance 9 Jan 2025

Why Vaccine Stocks, Lucid (LCID) Are Rallying

Vaccine stocks and EV maker Lucid Technologies (LCID) are among today’s biggest winners today. Va...

Insider Monkey · via Yahoo Finance 7 Jan 2025

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis ...

Zacks · via Yahoo Finance 7 Jan 2025